Inhibikase Therapeutics Inc. (IKT) Social Stream
Inhibikase Therapeutics Inc (IKT) Price Targets From Analysts
Use the tables below to see what analysts covering Inhibikase Therapeutics Inc think about its future price and what recommendations they have for investors and traders.
| Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|
| 2 | $15 | $12 | $13.5 | $2.12 | 536.79% |
The Trend in the Analyst Price Target
IKT's average price target has moved down $0 over the prior 46 days.
Over the past 123 days, IKT's average upside potential has been 436.62%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-09-20 | 2 | 15 | 12 | 13.5 | 2.050 | 558.54% |
| 2021-09-19 | 2 | 15 | 12 | 13.5 | 2.040 | 561.76% |
| 2021-09-18 | 2 | 15 | 12 | 13.5 | 2.040 | 561.76% |
| 2021-09-11 | 2 | 15 | 12 | 13.5 | 2.290 | 489.52% |
| 2021-08-18 | 2 | 15 | 12 | 13.5 | 1.950 | 592.31% |
| 2021-08-14 | 2 | 15 | 12 | 13.5 | 1.910 | 606.81% |
| 2021-08-07 | 2 | 15 | 12 | 13.5 | 2.160 | 525% |
| 2021-08-05 | 2 | 15 | 12 | 13.5 | 2.300 | 486.96% |
| 2021-07-12 | 1 | 15 | 15 | 15.0 | 2.700 | 455.56% |
| 2021-07-10 | 1 | 15 | 15 | 15.0 | 2.720 | 451.47% |
| 2021-07-03 | 1 | 15 | 15 | 15.0 | 2.800 | 435.71% |
| 2021-06-15 | 1 | 15 | 15 | 15.0 | 4.035 | 271.75% |
| 2021-06-13 | 1 | 15 | 15 | 15.0 | 5.956 | 151.85% |
| 2021-06-05 | 1 | 15 | 15 | 15.0 | 5.260 | 185.17% |
| 2021-05-20 | 1 | 15 | 15 | 15.0 | 4.761 | 215.06% |
IKT Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.5 | 0 | 2 | 0 | 0 | 0 | 2 |
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for IKT as an investment opportunity.
- IKT has a higher upside potential (average analyst target price relative to current price) than 96.9% of all US stocks.
- Inhibikase Therapeutics Inc's number of analysts covering the stock is greater than 13.07% of Healthcare stocks.
- IKT has a higher average analyst price target than 25.34% of all US stocks.
- Inhibikase Therapeutics Inc's variance in analysts' estimates is lower than 73.77% of Pharmaceutical Products stocks.
In the Pharmaceutical Products industry, AYTU, UNCY and VTVT are the three stocks most similar to Inhibikase Therapeutics Inc regarding the price target and analyst recommendation information presented here.
Is IKT a Buy, Hold or Sell? See the POWR Ratings now!